BETTERLIFE PHARMA (BETRF) Financials
A multiple compares the market's price with a filed figure; it says what the market pays, not how the business is doing. The market capitalization is the vendor's as of Oct 26, 2026; every other figure is from the SEC filings on this page. Not financial advice.
Newest figures come from the 20-F for FY2025, filed Jun 2, 2025. Each column of the statement tables below links to the filing it was taken from, and every filing is listed on the BETRF SEC filings page.
This page shows BETTERLIFE PHARMA INC (BETRF) financial statements, including the income statement, balance sheet, cash flow statement, and key financial ratios. View 15 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).
BetterLife’s liability-heavy balance sheet is shrinking more slowly than its asset base, while financing costs rise amid reduced development spending.
In FY2025, liabilities equaled3372.6% of assets, and assets fell35.9% while liabilities declined only12.4% from FY2024. That combination points to a balance sheet where obligations remain disproportionately large relative to the resources reported against them.
Development spending contracted
Negative equity persisted through FY2025 at
Some figures from recent filings were inconsistent and were omitted from this summary.
Financial Health Signals
BETTERLIFE PHARMA INC does not currently provide enough eligible data for a peer-relative financial health score, so none is published. The metrics below are current.
Key Financial Metrics
Earnings & Revenue
BETTERLIFE PHARMA INC earned -$0.02 per diluted share (EPS) in fiscal year 2025. The change from the prior year is not meaningful, because that figure was zero or negative.
Not reported for fiscal year 2025.
Not reported for fiscal year 2025.
Not reported for fiscal year 2025.
Cash & Balance Sheet
BETTERLIFE PHARMA INC held $6K in cash as of fiscal year 2025; no long-term debt figure is on record for that period.
Not reported for fiscal year 2025.
Not reported for fiscal year 2025.
Margins & Returns
None of these metrics is reported for fiscal year 2025.
Capital Allocation
BETTERLIFE PHARMA INC invested $293K in research and development in fiscal year 2025. This represents a decrease of 31.2% from the prior year.
Not reported for fiscal year 2025.
Not reported for fiscal year 2025.
BETRF Income Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | FY2520-F | FY2420-F | FY2320-F | FY2220-F | FY2120-F | FY2020-F | FY1920-F | FY1820-F | FY1720-F | FY1620-F | FY1520-F | FY1420-F | FY1320-F | FY1220-F | FY1120-F |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| R&D Expenses | $293K-31.2% | $427K | N/A | $4.3M+1816.3% | $223K+362.0% | $48K-82.6% | $278K+294.9% | $70K | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| SG&A Expenses | N/A | N/A | N/A | N/A | N/A | N/A | N/A | $345K | N/A | N/A | N/A | $23K+24.7% | $18K | N/A | N/A |
| Operating Income | N/A | N/A | N/A | N/A | N/A | N/A | N/A | -$1.0M | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Interest Expense | $114K+235.5% | $34K+294.8% | $9K-78.9% | $41K+639.4% | $6K-84.8% | $36K+881.8% | $4K-86.5% | $27K+134.8% | $12K | N/A | N/A | $32Kn/m | -$24K | N/A | N/A |
| Income Tax | $0n/m | $0n/m | -$120K-191.4% | $131K | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Net Income | N/A | N/A | N/A | N/A | N/A | -$14.8Mn/m | -$7.0Mn/m | -$121K | N/A | N/A | N/A | N/A | N/A | $1.4Mn/m | -$3.0M |
| EPS (Basic) | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | -$0.11n/m | -$0.09n/m | -$0.18 | N/A | N/A | N/A |
| EPS (Diluted) | -$0.02n/m | -$0.02n/m | -$0.07n/m | -$0.13n/m | -$1.05 | -$0.98 | -$0.78 | N/A | N/A | -$0.11n/m | -$0.09n/m | -$0.18 | N/A | N/A | N/A |
| Diluted Shares (Avg) | N/A | N/A | N/A | 438,095n/m | 0 | 0 | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
Not reported in any period shown, so not listed: Revenue, Cost of Revenue, Gross Profit, EBITDA.
BETRF Balance Sheet
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | FY2520-F | FY2420-F | FY2320-F | FY2220-F | FY2120-F | FY2020-F | FY1920-F | FY1820-F | FY1720-F | FY1620-F | FY1520-F | FY1420-F | FY1320-F | FY1220-F | FY1120-F |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total Assets | $156K-35.9% | $243K+332.9% | $56K-93.9% | $915K-12.5% | $1.0M-86.6% | $7.8M-0.6% | $7.8M+1943.6% | $384K+189.3% | $133K+25.0% | $106K+8281.1% | $1K-80.4% | $6K+6.4% | $6K | N/A | N/A |
| Current Assets | N/A | N/A | $56K-93.8% | $900K-13.5% | $1.0M-60.5% | $2.6M+1491.1% | $165K+10.9% | $149K+15.0% | $130K+25.7% | $103K+10901.5% | $938-83.4% | $6K+19.7% | $5K | N/A | N/A |
| Cash & Equivalents | $6K-79.7% | $28K+348.3% | $6K-95.4% | $137K+12.9% | $121K-95.1% | $2.5M+4260.8% | $57K-11.8% | $65K-42.6% | $112K+56.9% | $72K+8437.6% | $839-10.7% | $939+97.6% | $475-76.8% | $2K | N/A |
| Short-Term Investments | N/A | N/A | N/A | N/A | N/A | N/A | N/A | $0n/m | $0n/m | $0n/m | $0n/m | $0n/m | $0n/m | $0 | N/A |
| Accounts Receivable | $8K-72.7% | $30K+129.0% | $13K-95.0% | $256K-37.1% | $407K+291.8% | $104K+206.9% | $34K | N/A | N/A | N/A | $99-97.9% | $5K | N/A | N/A | N/A |
| Long-Term Investments | N/A | N/A | N/A | N/A | N/A | N/A | N/A | $0n/m | $0n/m | $0n/m | $0n/m | $0n/m | $0n/m | $0 | N/A |
| Goodwill | N/A | N/A | N/A | N/A | $0-100.0% | $606K-90.5% | $6.4M | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Total Liabilities | $5.2M-12.4% | $6.0M+5.0% | $5.7M+43.7% | $4.0M-15.1% | $4.7M+10.6% | $4.2M-18.4% | $5.2M+1107.7% | $429K-73.3% | $1.6M+269.3% | $435K+678.7% | $56K-91.8% | $682K+0.1% | $681K | N/A | N/A |
| Current Liabilities | $5.2M-5.0% | $5.5M+2.4% | $5.4M+64.2% | $3.3M-28.7% | $4.6M+530.2% | $726K-82.3% | $4.1M+858.0% | $429K-73.3% | $1.6M+269.3% | $435K+678.7% | $56K-91.5% | $656K-1.1% | $663K | N/A | N/A |
| Non-Current Liabilities | $34K-93.2% | $503K+45.6% | $346K-51.2% | $708K+587.6% | $103K-97.1% | $3.5M+227.0% | $1.1Mn/m | $0n/m | $0n/m | $0n/m | $0-100.0% | $26K+40.6% | $18K | N/A | N/A |
| Long-Term Debt | N/A | $37Kn/m | $0-100.0% | $27Kn/m | $0 | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Total Equity | -$5.1Mn/m | -$5.7Mn/m | -$5.7Mn/m | -$3.1Mn/m | -$3.6M-279.7% | $2.0M-24.5% | $2.7Mn/m | -$45Kn/m | -$1.5Mn/m | -$329Kn/m | -$55Kn/m | -$675Kn/m | -$675Kn/m | -$1.0Mn/m | -$2.9M |
| Retained Earnings | -$82.0Mn/m | -$86.0Mn/m | -$84.1Mn/m | -$81.3Mn/m | -$71.2Mn/m | -$41.3Mn/m | -$26.7Mn/m | -$20.7Mn/m | -$20.6Mn/m | -$14.3Mn/m | -$3.3Mn/m | -$2.6M | N/A | N/A | N/A |
Not reported in any period shown, so not listed: Inventory.
BETRF Cash Flow Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | FY2520-F | FY2420-F | FY2320-F | FY2220-F | FY2120-F | FY2020-F | FY1920-F | FY1820-F | FY1720-F | FY1620-F | FY1520-F | FY1420-F | FY1320-F | FY1220-F | FY1120-F |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | N/A | N/A | N/A | N/A | N/A | -$6.0Mn/m | -$3.6Mn/m | -$396Kn/m | -$359Kn/m | -$164K | N/A | -$25K | N/A | N/A | N/A |
| Depreciation & Amortization | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | $322-10.0% | $358-12.6% | $409-10.1% | $455 | N/A | N/A |
| Stock-Based Compensation | N/A | N/A | N/A | N/A | N/A | N/A | N/A | $52K-99.0% | $5.0M-15.2% | $5.9M | N/A | N/A | N/A | N/A | N/A |
| Capital Expenditures | N/A | N/A | N/A | N/A | $8K-98.1% | -$411Kn/m | $0 | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Free Cash Flow | N/A | N/A | N/A | N/A | N/A | -$6.4Mn/m | -$3.6M | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Investing Cash Flow | N/A | N/A | N/A | N/A | -$56Kn/m | -$863Kn/m | -$643K | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Financing Cash Flow | N/A | N/A | N/A | N/A | $3.2M-65.4% | $9.2M+119.0% | $4.2M+1071.3% | $361K-5.1% | $380K+58.1% | $240K | N/A | $25K-16.6% | $30K | N/A | N/A |
Not reported in any period shown, so not listed: Dividends Paid, Share Buybacks.
BETRF Financial Ratios
Margins and returns are percentages; the remaining ratios are unitless multiples. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | FY2520-F | FY2420-F | FY2320-F | FY2220-F | FY2120-F | FY2020-F | FY1920-F | FY1820-F | FY1720-F | FY1620-F | FY1520-F | FY1420-F | FY1320-F | FY1220-F | FY1120-F |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Return on Equity | N/A | N/A | N/A | N/A | N/A | -737.4%-472.6pp | -264.8% | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Return on Assets | N/A | N/A | N/A | N/A | N/A | -190.1%-100.3pp | -89.8%-58.2pp | -31.6% | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Current Ratio | N/A | N/A | 0.01-0.3x | 0.280.0x | 0.23-3.4x | 3.63+3.6x | 0.04-0.3x | 0.35+0.3x | 0.08-0.2x | 0.24+0.2x | 0.020.0x | 0.010.0x | 0.01 | N/A | N/A |
| Liabilities-to-Equity | N/A | N/A | N/A | N/A | N/A | 2.11+0.2x | 1.95 | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
Not reported in any period shown, so not listed: Gross Margin, Operating Margin, Net Margin, Debt-to-Equity, Asset Turnover, FCF Margin.
Note: Shareholder equity is negative (-$5.1M), which causes the debt-to-equity, liabilities-to-equity and return on equity ratios to appear negative or not meaningful. This can occur from accumulated losses or large share buyback programs.
Similar Companies
Newest fiscal year on record for each company. The health score is the peer-relative Financial Health Score for that year; a dash means no score is published for it.
| Company | Fiscal year | Revenue | Net income | Net margin | Market cap | Health score |
|---|---|---|---|---|---|---|
| BETTERLIFE PHARMA INC BETRF | FY2025 | N/A | N/A | N/A | $102.8M | — |
| ZEO SCIENTIFIX INC ZEOX | FY2025 | $5.2M | -$5.5M | N/A | $11.8M | — |
Where BETTERLIFE PHARMA INC Ranks
Frequently Asked Questions
What are BETTERLIFE PHARMA INC's total assets?
BETTERLIFE PHARMA INC (BETRF) had $156K in total assets as of fiscal year 2025, including both current and long-term assets.
How much does BETTERLIFE PHARMA INC spend on research and development?
BETTERLIFE PHARMA INC (BETRF) invested $293K in research and development during fiscal year 2025.
What is BETTERLIFE PHARMA INC's P/E ratio?
BETTERLIFE PHARMA INC (BETRF) has no price-to-earnings ratio at the moment: no net income reported. The market capitalization is $102.8M as of Oct 26, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.
What is BETTERLIFE PHARMA INC's price-to-sales ratio?
BETTERLIFE PHARMA INC (BETRF) has no price-to-sales ratio at the moment: no revenue reported. The market capitalization is $102.8M as of Oct 26, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.
Why is BETTERLIFE PHARMA INC's debt-to-equity ratio negative or not reported?
BETTERLIFE PHARMA INC (BETRF) has negative shareholder equity of -$5.1M as of fiscal year 2025, so no debt-to-equity or liabilities-to-equity ratio is reported: dividing debt by equity that is not positive produces a number that cannot be read as leverage. This can occur when accumulated losses exceed invested capital, or after large share buyback programs. Other solvency metrics like the current ratio or interest coverage may be more informative.